Evidence map›Paper›PMID 37153624›Full record

ArticleFrontiers in immunology2023

Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants.

Meagan M Jenkins, Donna Phan Tran, Evelyn A Flores, Deborah Kupferwasser, Harry Pickering, Ying Zheng, David W Gjertson, Ted M Ross, Joanna M Schaenman, Loren G Miller and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meagan M JenkinsDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Donna Phan TranLundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, United States.
Evelyn A FloresLundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, United States.
Deborah KupferwasserLundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, United States.
Harry PickeringDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Ying ZhengDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States.
David W GjertsonDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, GA, United States.
Joanna M SchaenmanDepartment of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, United States.
Loren G MillerLundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, United States.
Michael R YeamanDepartment of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, United States.
Elaine F ReedDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Training CoreTL1DK132768 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2021 to 2026
$3.4M
Network CoreU2CDK129496 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ISIDRO B. SALUSKY · 2021 to 2026
$2.9M
NCATS NIH HHS UL1 TR001881NIDDK NIH HHS TL1 DK132768NIDDK NIH HHS U2C DK129496NIH HHS 75N93019C00052
6 · The paper itself

Abstract

Introduction: SARS-CoV-2 is the etiologic agent of coronavirus disease 2019 (COVID-19). Questions remain regarding correlates of risk and immune protection against COVID-19. Methods: We prospectively enrolled 200 participants with a high risk of SARS-CoV-2 occupational exposure at a U.S. medical center between December 2020 and April 2022. Participant exposure risks, vaccination/infection status, and symptoms were followed longitudinally at 3, 6, and 12 months, with blood and saliva collection. Serological response to the SARS-CoV-2 spike holoprotein (S), receptor binding domain (RBD) and nucleocapsid proteins (NP) were quantified by ELISA assay. Results: Based on serology, 40 of 200 (20%) participants were infected. Healthcare and non-healthcare occupations had equivalent infection incidence. Only 79.5% of infected participants seroconverted for NP following infection, and 11.5% were unaware they had been infected. The antibody response to S was greater than to RBD. Hispanic ethnicity was associated with 2-fold greater incidence of infection despite vaccination in this cohort. Discussion: Overall, our findings demonstrate: 1) variability in the antibody response to SARS-CoV-2 infection despite similar exposure risk; 2) the concentration of binding antibody to the SARS-CoV-2 S or RBD proteins is not directly correlated with protection against infection in vaccinated individuals; and 3) determinants of infection risk include Hispanic ethnicity despite vaccination and similar occupational exposure.

Indexed as

COVID-19VaccinationAntibodiesCOVID-19 VaccinesEthnicityHispanic or LatinoHumansNucleocapsid ProteinsOccupational ExposureSARS-CoV-2AntibodiesCOVID-19 VaccinesNucleocapsid ProteinsCOVID-19high-riskinfectionSARS-CoV-2serological analysisvaccination

Identifiers

PMID37153624
PMCPMC10154521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.